These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 14726703)
21. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360 [TBL] [Abstract][Full Text] [Related]
22. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Bellantuono I; Gao L; Parry S; Marley S; Dazzi F; Apperley J; Goldman JM; Stauss HJ Blood; 2002 Nov; 100(10):3835-7. PubMed ID: 12411326 [TBL] [Abstract][Full Text] [Related]
23. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136 [TBL] [Abstract][Full Text] [Related]
24. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537 [TBL] [Abstract][Full Text] [Related]
25. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. DiBrino M; Tsuchida T; Turner RV; Parker KC; Coligan JE; Biddison WE J Immunol; 1993 Dec; 151(11):5930-5. PubMed ID: 7504010 [TBL] [Abstract][Full Text] [Related]
26. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853 [TBL] [Abstract][Full Text] [Related]
27. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519 [TBL] [Abstract][Full Text] [Related]
28. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743 [TBL] [Abstract][Full Text] [Related]
29. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347 [TBL] [Abstract][Full Text] [Related]
30. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen. Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105 [TBL] [Abstract][Full Text] [Related]
31. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528 [TBL] [Abstract][Full Text] [Related]
32. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients. Takedatsu H; Shichijo S; Katagiri K; Sawamizu H; Sata M; Itoh K Clin Cancer Res; 2004 Feb; 10(3):1112-20. PubMed ID: 14871991 [TBL] [Abstract][Full Text] [Related]
33. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433 [TBL] [Abstract][Full Text] [Related]
34. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030 [TBL] [Abstract][Full Text] [Related]
35. New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses. Parmiani G; Anichini A; Castelli C Melanoma Res; 1997 Aug; 7 Suppl 2():S95-8. PubMed ID: 9578423 [TBL] [Abstract][Full Text] [Related]
36. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861 [TBL] [Abstract][Full Text] [Related]
37. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Rivoltini L; Loftus DJ; Squarcina P; Castelli C; Rini F; Arienti F; Belli F; Marincola FM; Geisler C; Borsatti A; Appella E; Parmiani G Crit Rev Immunol; 1998; 18(1-2):55-63. PubMed ID: 9419448 [TBL] [Abstract][Full Text] [Related]
38. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808 [TBL] [Abstract][Full Text] [Related]
39. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655 [TBL] [Abstract][Full Text] [Related]
40. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Romero P; Valmori D; Pittet MJ; Zippelius A; Rimoldi D; Lévy F; Dutoit V; Ayyoub M; Rubio-Godoy V; Michielin O; Guillaume P; Batard P; Luescher IF; Lejeune F; Liénard D; Rufer N; Dietrich PY; Speiser DE; Cerottini JC Immunol Rev; 2002 Oct; 188():81-96. PubMed ID: 12445283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]